Health and wellness company Perrigo Company plc (NYSE:PRGO) reported on Thursday the receipt of approval from the US Food and Drug Administration (FDA) for the over-the-counter use of Nasonex 24HR Allergy (mometasone furoate monohydrate 50mcg).
This approval marks the first branded Rx-to-OTC switch for the company and paves the way for Nasonex to enter the OTC marketplace.
Perrigo expects to begin offering Nasonex 24HR Allergy later this year.
Mometasone furoate, is a steroid medication used to treat certain skin conditions, hay fever and asthma.
AstraZeneca wins US FDA approval for Tezspire in chronic rhinosinusitis with nasal polyps
ALK partners with GenSci to expand allergy immunotherapy market in China
Ionis publishes positive Phase 3 data supporting donidalorsen as HAE prophylactic
Blacksmith Medicines granted US patent for antibacterial compounds targeting LpxC
Alvotech reports positive topline results for Xolair biosimilar study
DBV Technologies secures up to USD306.9m to advance Viaskin peanut patch programme
Celltrion's OMLYCLO receives US FDA approval
Kenox Pharmaceuticals partners with Lactiga US
Health Canada approves ALK's ACARIZAX for young children with dust mite allergy
Allergy Therapeutics publishes positive Phase III data for Grass MATA MPL
CSL's ANDEMBRY receives European approval to prevent attacks of hereditary angioedema
NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS
European Commission approves Palforzia for toddlers with peanut allergy